The genomic diagnostics product developer secured $16.2m in a round led by Heda's healthcare investment arm, adding to a $9m series A in 2017.

The cell biology technology provider, which counts Nikon and Varian Medical among its investors, has raised about $215m in venture funding.

Wuxi AppTec and Pfizer have both contributed as the Yale University-founded cancer drug developer prepares for clinical testing next year.

SR One and Roche Venture Fund-backed Pandion Therapeutics will use the proceeds from the offering to advance a lead drug candidate for ulcerative colitis.

Syncona supplied a third of the investment and retains a majority stake in Freeline, which is based on research at UCL.

Wuxi AppTec and Pfizer contributed to a series A round that will support progress of Simcha Therapeutics' immuno-oncology treatments toward clinical trials.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Facit exited McMaster University's cancer radiotherapy spinout in an upsized initial public offering after $158m in funding.

OneProjects, an irregular heartbeat imaging system developer assisted by two Irish universities, will use the cash to pursue commercialisation in the US.

The hearing loss treatment developer, which counts Novartis Venture Fund and Partners Innovation Fund as investors, floated above its range.